Last reviewed · How we verify
Intravitreal injection of bevacizumab
Bevacizumab is a monoclonal antibody that blocks vascular endothelial growth factor (VEGF), inhibiting abnormal blood vessel formation in the eye.
Bevacizumab is a monoclonal antibody that blocks vascular endothelial growth factor (VEGF), inhibiting abnormal blood vessel formation in the eye. Used for Age-related macular degeneration (AMD), wet form, Diabetic macular edema (DME), Retinal vein occlusion (RVO).
At a glance
| Generic name | Intravitreal injection of bevacizumab |
|---|---|
| Also known as | Avastin |
| Sponsor | Barnes Retina Institute |
| Drug class | VEGF inhibitor (monoclonal antibody) |
| Target | VEGF (vascular endothelial growth factor) |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
By binding to VEGF, bevacizumab prevents the growth and proliferation of pathological neovascular tissue that characterizes conditions like wet age-related macular degeneration and diabetic retinopathy. When injected directly into the vitreous cavity, it reaches high local concentrations to suppress retinal and choroidal neovascularization, reducing fluid leakage and vision loss.
Approved indications
- Wet age-related macular degeneration
- Diabetic macular edema
- Retinal vein occlusion
- Proliferative diabetic retinopathy
Common side effects
- Endophthalmitis (intraocular infection)
- Cataract progression
- Retinal detachment
- Floaters/vitreous opacities
- Intraocular pressure elevation
Key clinical trials
- Speculum-Free Intravitreal Injection Using Cotton-Tipped Applicator Retraction: A Randomized Trial of Pain, Procedure Time, Patient Satisfaction, and Safety (NA)
- Clinical Study to Evaluate PRO-169 for Diabetic Macular Edema (PHASE3)
- Safety and Immunogenicity of PRO-169 in Patients With Diabetic Macular Edema (PHASE1)
- Bevacizumab Treatment For Type 1 ROP (PHASE2)
- Comparison of Bevacizumab and Aflibercept in Treatment of Diabetic Macular Edema (NA)
- Interest of Intravitreal Injections of Anti-VEGF as Initial and Adjuvant Treatment in Coats Disease (PHASE3)
- The Sahlgrenska Anti-VEGF Study (PHASE2)
- Pharmacogenomics of antiVEGF in Patients With Age-Associated Macular Degeneration (AMD) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |